PRESS RELEASE: BioSymetrics Collaborates with Janssen and Sema4 to Predict the Onset of COVID-19
Janssen Pharmaceuticals and Sema4 partnership announcement on projects using BioSymetrics Contingent AI platform
Drug Repurposing Prediction Using AI and SARS-CoV-2 High-Content Imaging Screening Data
We were recently approached by a clinical-stage biotech client to investigate the potential repositioning of one of their lead compounds used to treat COPD. Specifically, we wanted to know whether this compound would have any activity against SARS-CoV-2.It all begins with an idea.
Explore Drug Effects Against SARS-CoV-2 Phenotypic Screening
Remdesivir shows strong, dose-dependent therapeutic effects against SARS-CoV-2 in phenotypic screening. Our interactive COVID-19 blog lets you explore the data.
Predicting Mechanism of Action Using AI - Webinar
In this webinar, Mikalai Malinouski Ph.D.demonstrated how BioSymetrics uses AI in the prediction of mechanism of action (MOA), and provided a an example of how machine learning workflows can benefit both novel drug discovery and drug repositioning.
Uniting Against COVID-19
Already working with clinicians, leveraging international collaborations to put prediction platforms in place, and re-investigating our drug lead pipeline, BioSymetrics will pursue any collaboration to have a positive impact against COVID and support the heroes working tirelessly in the hospitals and clinics around the world.
Mitigating Batch Effects in Cell Painting Data
With the advent of high content screening methodologies (e.g. cellular imaging, transcriptomics, etc.), it becomes more challenging to tease apart and visualize batch effects. This is further compounded when building machine learning models which can easily use these confounding variables instead of real biological signal to generate predictions leading to poor real world relevance.
De-noising CMap L1000 Data
As with any assay, L1000 data is noisy. Experimental replicates (the same compound tested on the same cell line under the same conditions) often result in different levels of expression being measured. The process of de-noising the L1000 data makes it easier to see true assay response, and pick a representative concentration for each compound.
When are Two Compounds the Same?
When are two compounds the same? The effect of Simplified Molecular Input Line Entry System (SMILES) format on chemical database overlap including best practice for canonicalization and harmonization to understand the impact of these compound effects on a particular dataset and specific application.
Dealing with Missing Values in Healthcare Data
In this post, we highlight the challenges of missing values when modelling with time-series data of EMRs and discuss some techniques to address it.
Phenotype/Mechanism Prediction
Use Case: BioSymetrics ML framework generates structure-based activity predictions using phenotypic assays and HCS data to identify protein targets and affected pathways
Bias Reduction in HCS Data
Bias Reduction in High Content Screening can be solved using BioSymetrics Augusta™ machine learning platform.
Talking BioTech Podcast
Dr. Kevin Folta discusses how the genomics era has generated tremendous data sets, yet the information they reveal is limited by the human biases that search them. Are there ways to examine complex data sets for hidden patterns that can unearth new perspectives in biology? This is the role of machine learning, and the patterns form the basis of artificial intelligence that then executes new tasks. While these concepts seem difficult to fathom, Dr. Gabe Musso makes them understandable, and describes the ways they may be applied in contemporary contexts.
The Business of Healthcare Podcast
Anthony Iacovone, Chairman of BioSymetrics, joins host Dr. Bob Kaiser for a discussion about what biomedical artificial intelligence and machine learning are and how they can be used to improve outcomes in the areas of drug discovery, clinical diagnostics and value-based care as well as reduce healthcare costs.
BioSymetrics Launches Augusta™ Architect
Newest component to Augusta AI platform, the first biomedical machine learning framework, enables users to reduce bias, increase speed to market and improve patient outcomes
Collision Conference Interview | Canada's Podcast
Canada's Podcast talks to the entrepreneurs who are making it happen throughout Canada. A national podcast company that creates an active online community for entrepreneurs so they can stay connected locally and to let the world know what’s going on in Canada.